Dechra Pharmaceuticals : Acquisition of Ampharmco LLC, USA

Thursday, 29 August 2019

Dechra^® Pharmaceuticals PLC

(Dechra, Group, Company)

Acquisition

The Board of Dechra is pleased to announce the acquisition of Ampharmco LLC (APC) and its associated holding companies, Dragon Fire Holdings LLC and Black Griffin Holdings LLC together with its manufacturing site based in Fort Worth, Texas, for a cash consideration of USD 30.0 million (£24.5 million)¹.

APC was originally founded in 1999 as a veterinary contract manufacturer specialising in companion animal products (CAP) and subsequently received FDA approval for two veterinary generic products, one of which, Gentamicin-Betamethasone Topical Spray, is currently marketed by Dechra. The other product, Carprofen Chewable Tablets, is currently marketed by another international animal health company. APC will also provide Dechra with an FDA registered facility to manufacture solid dose, liquids, creams and ointments, which will significantly strengthen our manufacturing capabilities for the North American market. APC also has a small pipeline of CAP products which will complement our existing US product portfolio.

Ian Page, Dechra's Chief Executive Officer commented: 'We are pleased to have completed the acquisition of APC which allows us to bring in-house manufacturing for a number of our currently outsourced products in the US market and will, in the longer term, also add to our US portfolio of approved CAP products.'

Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer	Office: [phone]
Paul Sandland, Acting Chief Financial Officer e-mail:[e-mail]	Office: [phone]
TooleyStreet Communications Ltd
Fiona Tooley, Director e-mail:[e-mail]	Mobile: [phone] Office: [phone]

Note

1) Translated at USD 1.22205: GBP 1.0000 (closing rate on 28 August 2019)

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Many of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. These novel products are complemented by a range of generics.

For more information, please visit:www.dechra.com.

Stock Code: Full Listing (Pharmaceuticals): DPH

LEI: 213800J4UVB5OWG8VX82

Trademarks

Dechra and the Dechra 'D' logo are registered trademarks of Dechra Pharmaceuticals PLC.

About AmPharmCo (APC)

AmPharmCo was co-founded in 1999 in Fort Worth, TX by Dr. Jerry B. Payne and Dr. Hsi-tang (Nick) Tung, two well-known veterinarians and microbiologists in the animal biologics industry. As a fully integrated company, APC has for the last 18 years focused on supporting pharmaceutical companies in taking their products from early development through to commercial manufacturing. It operates an FDA registered cGMP facility which occupies c.37,000 sq.ft. in Fort Worth, Texas, which is capable of providing manufacturing and analytical testing services for liquid, semi-solid, and solid dosage forms of drug products.

For more information, please visit:www.ampharmco.com.

Forward Looking Statement

This document may contain certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.